<DOC>
	<DOCNO>NCT00530764</DOCNO>
	<brief_summary>The purpose study determine effective dose range demonstrate non-effective dose range Sativex patient advance cancer , experience inadequate pain relief even though optimize chronic opioid therapy .</brief_summary>
	<brief_title>A Study SativexÂ® Pain Relief Patients With Advanced Malignancy .</brief_title>
	<detailed_description />
	<mesh_term>Dronabinol</mesh_term>
	<criteria>The patient advance active cancer know curative therapy . The patient able ( investigator opinion ) willing comply study requirement . The patient clinical diagnosis cancer relate pain , wholly alleviate current opioid treatment . The patient receiving sustain release ( SR ) fix dose opioid therapy ( exclude Methadone ) . N.B . The opiate therapy must Step III accord World Health Organization ( WHO ) analgesic ladder . The patient willing continue take regular daily baseline opioid regimen ( SR ) dose , throughout duration study . The patient exclude enter study receive due receive study period ; chemotherapy , hormone therapy radiotherapy , , opinion investigator affect pain . Any history immediate family history schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Any known suspected history diagnose dependence disorder , current heavy alcohol consumption , current use illicit drug current non prescribe use prescription drug . The patient poorly control epilepsy recurrent seizure ( i.e . least one year since last seizure ) . The patient experience myocardial infarction clinically relevant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put patient risk clinically relevant arrhythmia myocardial infarction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Palliative</keyword>
</DOC>